{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T15:10:47Z","timestamp":1789657847399,"version":"4.0.1"},"reference-count":110,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Cisplatin and carboplatin are central pillars of chemotherapy in solid tumor oncology, but their comparative efficacy and tolerability remain variably defined in the literature across tumor types and settings.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To quantify and grade the certainty of evidence comparing the efficacy and safety outcomes of cisplatin- and carboplatin-based systemic therapies through an umbrella review of published meta-analyses.<\/jats:p>\n <\/jats:sec>\n \n Data Sources<\/jats:title>\n Web of Science Core Collection databases from inception through January 11, 2026.<\/jats:p>\n <\/jats:sec>\n \n Study Selection<\/jats:title>\n Eligible studies were original meta-analyses of patients with solid tumors directly comparing both platinum-based regimens and reporting outcomes consisting of objective response rate, complete response, overall survival (OS), progression-free survival, disease-free survival, mortality or treatment failure ratio, and selected adverse events.<\/jats:p>\n <\/jats:sec>\n \n Data Extraction and Synthesis<\/jats:title>\n Effect sizes from individual studies were pooled and harmonized as equivalent odds ratios (eORs) through random-effects models. Certainty of evidence was classified with an algorithmic GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach. The umbrella meta-analysis followed the Preferred Reporting Items for Overviews of Reviews (PRIOR) reporting guidelines.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Outcomes were summarized as pooled eORs.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Eleven meta-analyses (including 52 unique studies and 12\u202f683 unique patients) were included across 7 tumor types. High-certainty evidence supported a higher objective response rate with cisplatin vs carboplatin in advanced urothelial carcinoma (8 studies; eOR, 1.38 [95% CI, 1.24-1.53];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) and no progression-free survival difference in advanced ovarian carcinoma (3 studies; eOR, 0.91 [95% CI, 0.81-1.03];\n P<\/jats:italic>\n \u2009=\u2009.09). Moderate-certainty evidence supported an increased complete response with cisplatin in early-stage cervical carcinoma (3 studies; eOR, 2.03 [95% CI, 1.27-3.24];\n P<\/jats:italic>\n \u2009=\u2009.02), while 3-year disease-free survival and OS did not show significant differences. In advanced non\u2013small cell lung cancer, 1-year OS (10 studies; eOR, 1.07 [95% CI, 0.89-1.27]) and mortality ratio (14 studies; eOR, 0.99 [95% CI, 0.98-1.01]) did not show differences, with moderate GRADE class. Peripheral neurotoxicity did not differ significantly, with moderate-certainty evidence. Ototoxicity, nephrotoxicity, and emesis were significantly higher with cisplatin, while hematologic toxicity, particularly thrombocytopenia, was significantly higher with carboplatin; heterogeneity was high and certainty was very low.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this umbrella meta-analysis comparing cisplatin- and carboplatin-based chemotherapy, the findings clarified the certainty of evidence regarding their comparative efficacy and safety. High-certainty findings were confined to urothelial and ovarian cancers. For most other tumor types, particularly for survival outcomes, estimates suggested no meaningful differences, with moderate to low certainty, highlighting important gaps in high-level evidence.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.34287","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T15:00:27Z","timestamp":1789657227000},"page":"e2634287","source":"Crossref","is-referenced-by-count":0,"title":["Reappraisal of Cisplatin vs Carboplatin Treatment for Solid Tumors"],"prefix":"10.1001","volume":"9","author":[{"given":"Pablo","family":"Jim\u00e9nez-Labaig","sequence":"first","affiliation":[{"name":"Head and Neck Unit, The Royal Marsden NHS (National Health Service) Foundation Trust, London, United Kingdom"},{"name":"Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, United Kingdom"},{"name":"Department of Medicine, Universidad Aut\u00f3noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriol","family":"Mirallas","sequence":"additional","affiliation":[{"name":"Department of Medicine, Universidad Aut\u00f3noma de Barcelona, Barcelona, Spain"},{"name":"Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Vall d\u2019Hebron Institute of Oncology, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipa","family":"Pereira","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Instituto Portugu\u00eas de Oncologia de Porto, Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Sanz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sant Pau University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enriqueta","family":"Felip","sequence":"additional","affiliation":[{"name":"Department of Medicine, Universidad Aut\u00f3noma de Barcelona, Barcelona, Spain"},{"name":"Vall d\u2019Hebron Institute of Oncology, Barcelona, Spain"},{"name":"Department of Medical Oncology, Vall d\u2019Hebron University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Rodon","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoleta","family":"Colombo","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Program, European Institute of Oncology, Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Galsky","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine, Mount Sinai Cancer Center, Tisch Cancer Institute, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Harrington","sequence":"additional","affiliation":[{"name":"Head and Neck Unit, The Royal Marsden NHS (National Health Service) Foundation Trust, London, United Kingdom"},{"name":"Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"issue":"35","key":"zoi260929r1","doi-asserted-by":"publisher","first-page":"4219","DOI":"10.1200\/JCO.2015.60.7481","article-title":"Platinum antitumor complexes: 50 years since Barnett Rosenberg\u2019s discovery.","volume":"33","author":"Muggia","year":"2015","journal-title":"J Clin Oncol"},{"issue":"11","key":"zoi260929r2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-013072","article-title":"Second-event endpoints (EFS2, PRFS2 and PFS2) after anti-PD-(L)1-based RCTs: a systematic review and meta-analysis.","volume":"13","author":"Jimenez-Labaig","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"2","key":"zoi260929r3","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/annonc\/mdy551","article-title":"Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors.","volume":"30","author":"Heinhuis","year":"2019","journal-title":"Ann Oncol"},{"key":"zoi260929r4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.critrevonc.2016.03.014","article-title":"Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies.","volume":"102","author":"Ho","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"zoi260929r5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/annonc\/4.suppl_4.S41","article-title":"Advanced ovarian cancer: carboplatin versus cisplatin.","volume":"4","author":"Vermorken","year":"1993","journal-title":"Ann Oncol"},{"issue":"3","key":"zoi260929r6","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/00000421-199206000-00012","article-title":"A phase II trial of continuous infusion cisplatin and 5-fluorouracil with oral calcium leucovorin in colorectal carcinoma.","volume":"15","author":"Posner","year":"1992","journal-title":"Am J Clin Oncol"},{"issue":"23","key":"zoi260929r7","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1056\/NEJMoa032709","article-title":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.","volume":"350","author":"Andr\u00e9","year":"2004","journal-title":"N Engl J Med"},{"issue":"19","key":"zoi260929r8","doi-asserted-by":"publisher","first-page":"6645","DOI":"10.1039\/C8DT00838H","article-title":"The side effects of platinum-based chemotherapy drugs: a review for chemists.","volume":"47","author":"Oun","year":"2018","journal-title":"Dalton Trans"},{"key":"zoi260929r9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/0305-7372(85)90018-0","article-title":"Phase I studies with carboplatin at the Royal Marsden Hospital.","volume":"12","author":"Calvert","year":"1985","journal-title":"Cancer Treat Rev"},{"issue":"19","key":"zoi260929r10","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1056\/NEJMoa032641","article-title":"Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.","volume":"350","author":"Bernier","year":"2004","journal-title":"N Engl J Med"},{"issue":"19","key":"zoi260929r11","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMoa032646","article-title":"Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck.","volume":"350","author":"Cooper","year":"2004","journal-title":"N Engl J Med"},{"issue":"7","key":"zoi260929r12","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1093\/jnci\/dji084","article-title":"Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma.","volume":"97","author":"Chan","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"zoi260929r13","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.eururo.2021.09.028","article-title":"Adjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and meta-analysis of individual participant data from randomised controlled trials.","volume":"81","author":"Advanced Bladder Cancer (ABC) Meta-analysis Collaborators Group","year":"2022","journal-title":"Eur Urol"},{"issue":"5","key":"zoi260929r14","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1097\/JTO.0000000000000146","article-title":"Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer: an analysis of Veterans Health Administration data.","volume":"9","author":"Santana-Davila","year":"2014","journal-title":"J Thorac Oncol"},{"issue":"11","key":"zoi260929r15","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1093\/jnci\/djk196","article-title":"Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis.","volume":"99","author":"Ardizzoni","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"14","key":"zoi260929r16","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1200\/JCO.2011.40.4905","article-title":"Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data.","volume":"30","author":"Rossi","year":"2012","journal-title":"J Clin Oncol"},{"issue":"19","key":"zoi260929r17","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1200\/JCO.2014.58.4391","article-title":"Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505.","volume":"33","author":"Kitagawa","year":"2015","journal-title":"J Clin Oncol"},{"key":"zoi260929r19","doi-asserted-by":"publisher","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both.","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"issue":"1","key":"zoi260929r20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjment-2022-300534","article-title":"metaumbrella: The first comprehensive suite to perform data analysis in umbrella reviews with stratification of the evidence.","volume":"26","author":"Gosling","year":"2023","journal-title":"BMJ Ment Health"},{"issue":"1","key":"zoi260929r21","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12874-015-0091-1","article-title":"Hartung-Knapp-Sidik-Jonkman approach and its modification for random-effects meta-analysis with few studies.","volume":"15","author":"R\u00f6ver","year":"2015","journal-title":"BMC Med Res Methodol"},{"issue":"2","key":"zoi260929r22","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1093\/annonc\/mdr156","article-title":"Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma.","volume":"23","author":"Galsky","year":"2012","journal-title":"Ann Oncol"},{"issue":"6","key":"zoi260929r23","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102176","article-title":"Split-dose cisplatin in patients with locally advanced or metastatic urothelial carcinoma: a systematic literature review and network meta-analysis.","volume":"22","author":"O\u2019Dwyer","year":"2024","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"zoi260929r24","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.ygyno.2018.07.005","article-title":"The efficacy of concurrent weekly carboplatin with radiotherapy in the treatment of cervical cancer: a meta-analysis.","volume":"150","author":"Xue","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"12","key":"zoi260929r25","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.51011","article-title":"Comparison of the efficacy of cisplatin\/paclitaxel versus carboplatin\/paclitaxel in improving survival and quality of life in the advanced ovarian cancer patient population: a systematic review and meta-analysis of randomized control trials.","volume":"15","author":"Mansoor","year":"2023","journal-title":"Cureus"},{"key":"zoi260929r26","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.lungcan.2019.07.010","article-title":"Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: a meta-analysis.","volume":"135","author":"Griesinger","year":"2019","journal-title":"Lung Cancer"},{"issue":"8","key":"zoi260929r27","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009256.pub2","article-title":"Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.","author":"de Castria","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"zoi260929r28","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920965841","article-title":"Systematic review of first-line chemotherapy for chemo-na\u00efve extensive-stage small-cell lung cancer: network meta-analysis.","volume":"12","author":"Chen","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"zoi260929r29","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2025.36.e49","article-title":"Comparison of carboplatin-based chemotherapy versus cisplatin-based chemotherapy in the treatment of malignant gonadal germ cell tumor: a systematic review and meta-analysis.","volume":"36","author":"Zhang","year":"2025","journal-title":"J Gynecol Oncol"},{"issue":"6","key":"zoi260929r30","doi-asserted-by":"publisher","first-page":"7110","DOI":"10.18632\/oncotarget.6858","article-title":"A meta-analysis comparing cisplatin-based to carboplatin-based chemotherapy in moderate to advanced squamous cell carcinoma of head and neck (SCCHN).","volume":"7","author":"Guan","year":"2016","journal-title":"Oncotarget"},{"key":"zoi260929r31","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ejca.2018.03.004","article-title":"Comparison of carboplatin versus cisplatin in the treatment of paediatric extracranial malignant germ cell tumours: a report of the Malignant Germ Cell International Consortium.","volume":"98","author":"Frazier","year":"2018","journal-title":"Eur J Cancer"},{"issue":"2","key":"zoi260929r32","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ygyno.2018.05.025","article-title":"Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults?","volume":"150","author":"Shah","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"11","key":"zoi260929r33","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1002\/1097-0142(19900601)65:11<2465::AID-CNCR2820651112>3.0.CO;2-7","article-title":"Carboplatin, etoposide, and bleomycin for patients with poor-risk germ cell tumors.","volume":"65","author":"Motzer","year":"1990","journal-title":"Cancer"},{"issue":"3","key":"zoi260929r34","first-page":"188","article-title":"A randomized phase II trial of paclitaxel in combination chemotherapy with platinum in the treatment of non-small cell lung cancer.","volume":"4","author":"Yan","year":"2001","journal-title":"Zhongguo Fei Ai Za Zhi"},{"issue":"2","key":"zoi260929r35","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/(SICI)1097-0142(19960115)77:2<344::AID-CNCR18>3.0.CO;2-1","article-title":"Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients: a randomized phase II study.","volume":"77","author":"Petrioli","year":"1996","journal-title":"Cancer"},{"issue":"10","key":"zoi260929r36","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/(SICI)1097-0142(19971115)80:10<1966::AID-CNCR14>3.0.CO;2-W","article-title":"Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma.","volume":"80","author":"Bellmunt","year":"1997","journal-title":"Cancer"},{"issue":"8","key":"zoi260929r37","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/cncr.20123","article-title":"Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium.","volume":"100","author":"Dreicer","year":"2004","journal-title":"Cancer"},{"issue":"1","key":"zoi260929r38","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.eururo.2006.12.029","article-title":"Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial.","volume":"52","author":"Dogliotti","year":"2007","journal-title":"Eur Urol"},{"issue":"6","key":"zoi260929r39","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1200\/JCO.2020.38.6_suppl.461","article-title":"Vefora, GETUG-AFU V06 study: randomized multicenter phase II\/III trial of fractionated cisplatin (CI)\/gemcitabine (G) or carboplatin (CA)\/g in patients (pts) with advanced urothelial cancer (UC) with impaired renal function (IRF)\u2014results of a planned interim analysis.","volume":"38","author":"Mourey","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi260929r40","doi-asserted-by":"crossref","first-page":"167","DOI":"10.21873\/invivo.11454","article-title":"Gemcitabine plus cisplatin split versus gemcitabine plus carboplatin for advanced urothelial cancer with cisplatin-unfit renal function.","volume":"33","author":"Izumi","year":"2019","journal-title":"In Vivo"},{"issue":"1","key":"zoi260929r41","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00280-015-2774-z","article-title":"Gemcitabine plus split-dose cisplatin could be a promising alternative to gemcitabine plus carboplatin for cisplatin-unfit patients with advanced urothelial carcinoma.","volume":"76","author":"Kim","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"zoi260929r42","first-page":"1","article-title":"Real-world treatment patterns and overall survival in locally advanced and metastatic urothelial tract cancer patients treated with chemotherapy in Denmark in the preimmunotherapy era: a nationwide, population-based study.","volume":"24","author":"Omland","year":"2020","journal-title":"Eur Urol Open Sci"},{"key":"zoi260929r43","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ejogrb.2016.03.016","article-title":"Carboplatin-based chemoradiotherapy in advanced cervical cancer: an alternative to cisplatin-based regimen?","volume":"201","author":"Sebasti\u00e3o","year":"2016","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"15","key":"zoi260929r44","article-title":"Which is better? carboplatin versus cisplatin for locally advanced cervical cancer: Peruvian experience.","volume":"35","author":"Valdivieso","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7","key":"zoi260929r45","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1634\/theoncologist.2012-0455","article-title":"Comparison of carboplatin- and cisplatin-based concurrent chemoradiotherapy in locally advanced cervical cancer patients with morbidity risks.","volume":"18","author":"Nam","year":"2013","journal-title":"Oncologist"},{"issue":"17","key":"zoi260929r46","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1200\/JCO.2000.18.17.3084","article-title":"Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.","volume":"18","author":"Neijt","year":"2000","journal-title":"J Clin Oncol"},{"issue":"17","key":"zoi260929r47","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer.","volume":"95","author":"du Bois","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"30","key":"zoi260929r48","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1200\/JCO.2006.07.7016","article-title":"Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer.","volume":"24","author":"Socinski","year":"2006","journal-title":"J Clin Oncol"},{"issue":"7","key":"zoi260929r49","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/oxfordjournals.annonc.a058931","article-title":"Randomized comparison of etoposide-cisplatin vs etoposide-carboplatin and irradiation in small-cell lung cancer: a Hellenic Co-operative Oncology Group study.","volume":"5","author":"Skarlos","year":"1994","journal-title":"Ann Oncol"},{"issue":"2","key":"zoi260929r50","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/sj.bjc.6603810","article-title":"Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702.","volume":"97","author":"Okamoto","year":"2007","journal-title":"Br J Cancer"},{"issue":"1","key":"zoi260929r51","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/oxfordjournals.annonc.a059039","article-title":"Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? a randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine.","volume":"6","author":"Joss","year":"1995","journal-title":"Ann Oncol"},{"issue":"9","key":"zoi260929r52","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1200\/JCO.1990.8.9.1556","article-title":"A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861.","volume":"8","author":"Klastersky","year":"1990","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi260929r53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0169-5002(01)00239-2","article-title":"Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study.","volume":"34","author":"Jelic","year":"2001","journal-title":"Lung Cancer"},{"issue":"346a","key":"zoi260929r54","article-title":"E L. Randomized phase II study of tirapazamine with either cisplatin or carboplatin in advanced NSCLC.","volume":"20","author":"Bisset","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"10","key":"zoi260929r55","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/annonc\/mdf332","article-title":"Phase III randomised trial comparing paclitaxel\/carboplatin with paclitaxel\/cisplatin in patients with advanced non\u2013small-cell lung cancer: a cooperative multinational trial.","volume":"13","author":"Rosell","year":"2002","journal-title":"Ann Oncol"},{"issue":"2","key":"zoi260929r56","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non\u2013small-cell lung cancer.","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi260929r57","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0169-5002(03)00233-2","article-title":"Gemcitabine plus cisplatin vs gemcitabine plus carboplatin in stage IIIb and IV non\u2013small cell lung cancer: a phase III randomized trial.","volume":"41","author":"Zatloukal","year":"2003","journal-title":"Lung Cancer"},{"issue":"16","key":"zoi260929r58","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1200\/JCO.2003.12.046","article-title":"Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non\u2013small-cell lung cancer: the TAX 326 study group.","volume":"21","author":"Fossella","year":"2003","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi260929r59","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0169-5002(03)00140-5","article-title":"Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non\u2013small cell lung cancer.","volume":"41","author":"Mazzanti","year":"2003","journal-title":"Lung Cancer"},{"issue":"1","key":"zoi260929r60","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0169-5002(03)00280-0","article-title":"Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer: a multicenter, randomized phase III trial.","volume":"43","author":"Paccagnella","year":"2004","journal-title":"Lung Cancer"},{"issue":"10","key":"zoi260929r61","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1002\/1097-0142(20011115)92:10<2639::AID-CNCR1617>3.0.CO;2-8","article-title":"Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase II trial in patients with metastatic nonsmall cell lung carcinoma.","volume":"92","author":"Sweeney","year":"2001","journal-title":"Cancer"},{"issue":"6","key":"zoi260929r62","first-page":"427","article-title":"Comparison of efficacy and toxicity between gemcitabine plus carboplatin and gemcitabine plus cisplatin in the treatment of advanced non-small cell lung cancer.","volume":"5","author":"Cai","year":"2002","journal-title":"Zhongguo Fei Ai Za Zhi"},{"issue":"2","key":"zoi260929r63","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1556-0864(15)31529-X","article-title":"A phase II randomized study of paclitaxel plus carboplatin or cisplatin against chemo-naive inoperable non\u2013small cell lung cancer in the elderly.","volume":"1","author":"Chen","year":"2006","journal-title":"J Thorac Oncol"},{"issue":"2","key":"zoi260929r64","doi-asserted-by":"crossref","first-page":"198","DOI":"10.4103\/0973-1482.187287","article-title":"A prospective randomized controlled study of cisplatin versus carboplatin-based regimen in advanced squamous nonsmall cell lung cancer.","volume":"13","author":"Saad","year":"2017","journal-title":"J Cancer Res Ther"},{"issue":"3","key":"zoi260929r65","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cllc.2012.10.001","article-title":"A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non\u2013small-cell lung cancer.","volume":"14","author":"Schuette","year":"2013","journal-title":"Clin Lung Cancer"},{"key":"zoi260929r66","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ejca.2017.05.037","article-title":"Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non\u2013small-cell lung cancer: results from a British Thoracic Oncology Group randomised phase III trial.","volume":"83","author":"Ferry","year":"2017","journal-title":"Eur J Cancer"},{"issue":"1","key":"zoi260929r67","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1186\/s12885-016-2558-9","article-title":"Combined chemoradiation of cisplatin versus carboplatin in cervical carcinoma: a single institution experience from Thailand.","volume":"16","author":"Tharavichitkul","year":"2016","journal-title":"BMC Cancer"},{"issue":"1","key":"zoi260929r68","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1754-9485.2012.02463.x","article-title":"Radiation with cisplatin or carboplatin for locally advanced cervix cancer: the experience of a tertiary cancer centre.","volume":"57","author":"Au-Yeung","year":"2013","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"17","key":"zoi260929r69","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol"},{"issue":"7","key":"zoi260929r70","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.3390\/ijerph17072213","article-title":"Comparing paclitaxel-carboplatin with paclitaxel-cisplatin as the front-line chemotherapy for patients with FIGO IIIC serous-type tubo-ovarian cancer.","volume":"17","author":"Huang","year":"2020","journal-title":"Int J Environ Res Public Health"},{"issue":"6","key":"zoi260929r71","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/sj.bjc.6604272","article-title":"Intra-arterial chemoradiotherapy for locally advanced oral cavity cancer: analysis of therapeutic results in 134 cases.","volume":"98","author":"Fuwa","year":"2008","journal-title":"Br J Cancer"},{"issue":"6","key":"zoi260929r72","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.oraloncology.2013.02.004","article-title":"Equivalence of cisplatin and carboplatin-based chemoradiation for locally advanced squamous cell carcinoma of the head and neck: a matched-pair analysis.","volume":"49","author":"Wilkins","year":"2013","journal-title":"Oral Oncol"},{"issue":"5","key":"zoi260929r73","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/00130404-200409000-00010","article-title":"Randomized phase II trial of concomitant chemoradiotherapy using weekly carboplatin or daily low-dose cisplatin for squamous cell carcinoma of the head and neck.","volume":"10","author":"Homma","year":"2004","journal-title":"Cancer J"},{"issue":"9","key":"zoi260929r74","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ejca.2007.03.022","article-title":"Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: randomised, non-inferiority, open trial.","volume":"43","author":"Chitapanarux","year":"2007","journal-title":"Eur J Cancer"},{"issue":"2","key":"zoi260929r75","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.7314\/APJCP.2013.14.2.1121","article-title":"Carboplatin\/5-fluorouracil as an alternative to cisplatin\/5- fluorouracil for metastatic and recurrent head and neck squamous cell carcinoma and nasopharyngeal carcinoma.","volume":"14","author":"Kua","year":"2013","journal-title":"Asian Pac J Cancer Prev"},{"issue":"6","key":"zoi260929r76","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1200\/JCO.1995.13.6.1493","article-title":"Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer.","volume":"13","author":"De Andr\u00e9s","year":"1995","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi260929r77","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/thx.2007.093872","article-title":"Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer.","volume":"64","author":"Lee","year":"2009","journal-title":"Thorax"},{"key":"zoi260929r78","doi-asserted-by":"crossref","first-page":"A41","DOI":"10.1136\/thoraxjnl-2011-201054b.85","article-title":"S85 British Thoracic Oncology Group TriaL, BTOG2: randomised phase III clinical trial of gemcitabine combined with cisplatin 50 mg\/m2 (gc50) vs cisplatin 80 mg\/m2 (gc80) vs carboplatin auc 6 (gcb6) in advanced NSCLC.","volume":"66","author":"Ferry","year":"2011","journal-title":"Thorax"},{"issue":"5","key":"zoi260929r79","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/0277-5379(87)90305-1","article-title":"Chemotherapy of germ-cell ovarian tumours: first-line treatment with etoposide, bleomycin and cisplatin or carboplatin.","volume":"23","author":"Smales","year":"1987","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"8","key":"zoi260929r80","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/oxfordjournals.annonc.a058621","article-title":"Cisplatin-etoposide and carboplatin-etoposide induction chemotherapy for good-risk patients with germ cell tumors.","volume":"4","author":"Tjulandin","year":"1993","journal-title":"Ann Oncol"},{"issue":"10","key":"zoi260929r81","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/oxfordjournals.annonc.a010493","article-title":"A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with \u201cgood-risk\u201d metastatic non-seminomatous germ cell tumors.","volume":"7","author":"Bokemeyer","year":"1996","journal-title":"Ann Oncol"},{"issue":"5","key":"zoi260929r82","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1200\/JCO.1997.15.5.1844","article-title":"Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council\/European Organization for Research and Treatment of Cancer Trial.","volume":"15","author":"Horwich","year":"1997","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi260929r83","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1006\/gyno.1998.5047","article-title":"Favorable outcome of ovarian germ cell malignancies treated with cisplatin or carboplatin-based chemotherapy: a Hellenic Cooperative Oncology Group study.","volume":"70","author":"Dimopoulos","year":"1998","journal-title":"Gynecol Oncol"},{"issue":"1","key":"zoi260929r84","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s00066-011-0005-z","article-title":"Cisplatin superior to carboplatin in adjuvant radiochemotherapy for locally advanced cancers of the oropharynx and oral cavity.","volume":"188","author":"Rades","year":"2012","journal-title":"Strahlenther Onkol"},{"issue":"13","key":"zoi260929r85","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma.","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"issue":"19","key":"zoi260929r86","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma.","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi260929r87","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.euo.2025.09.006","article-title":"Revisiting neoadjuvant chemotherapy in cisplatin-eligible muscle-invasive bladder cancer.","volume":"9","author":"Molina-Cerrillo","year":"2026","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"zoi260929r88","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines.","volume":"85","author":"Alfred Witjes","year":"2024","journal-title":"Eur Urol"},{"issue":"3","key":"zoi260929r89","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up.","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"},{"key":"zoi260929r90","doi-asserted-by":"crossref","first-page":"S1648","DOI":"10.1016\/j.annonc.2025.09.124","article-title":"LBA2 Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: the phase III KEYNOTE-905 study.","volume":"36","author":"Vulsteke","year":"2025","journal-title":"Ann Oncol"},{"issue":"12","key":"zoi260929r92","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma.","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi260929r93","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/annonc\/mdl401","article-title":"Feasibility, toxicity and quality of life of first-line chemotherapy with platinum\/paclitaxel in elderly patients aged >or=70 years with advanced ovarian cancer\u2014a study by the AGO OVAR Germany.","volume":"18","author":"Hilpert","year":"2007","journal-title":"Ann Oncol"},{"issue":"6","key":"zoi260929r94","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105125","article-title":"Pan-Asia adapted ESMO clinical practice guideline for the management of patients with newly diagnosed and relapsed epithelial ovarian cancer.","volume":"10","author":"Nag","year":"2025","journal-title":"ESMO Open"},{"issue":"17","key":"zoi260929r95","doi-asserted-by":"crossref","first-page":"10078","DOI":"10.3390\/ijms231710078","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC): an overview of the molecular and cellular mechanisms of actions and effects on epithelial ovarian cancers.","volume":"23","author":"Lim","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"10421","key":"zoi260929r96","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(23)02405-4","article-title":"Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.","volume":"403","author":"Oaknin","year":"2024","journal-title":"Lancet"},{"key":"zoi260929r97","doi-asserted-by":"crossref","first-page":"iv72","DOI":"10.1093\/annonc\/mdx220","article-title":"Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.","volume":"28","author":"Marth","year":"2017","journal-title":"Ann Oncol"},{"issue":"5","key":"zoi260929r98","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1136\/ijgc-2023-004429","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with cervical cancer\u2014update 2023.","volume":"33","author":"Cibula","year":"2023","journal-title":"Int J Gynecol Cancer"},{"issue":"10434","key":"zoi260929r99","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(24)00317-9","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.","volume":"403","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"zoi260929r100","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/S0360-3016(03)00347-X","article-title":"A phase I study of carboplatin concurrent with radiation in FIGO stage IIIB cervix uteri carcinoma.","volume":"56","author":"Duenas-Gonzalez","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"zoi260929r101","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1200\/JCO-25-02825","article-title":"Therapy for stage IV non\u2013small cell lung cancer without driver alterations: ASCO living guideline, 2026.3.0.","volume":"44","author":"Reuss","year":"2026","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi260929r102","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","article-title":"Non\u2013oncogene-addicted metastatic non\u2013small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"issue":"7","key":"zoi260929r103","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.","volume":"32","author":"Dingemans","year":"2021","journal-title":"Ann Oncol"},{"issue":"7","key":"zoi260929r104","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JOP.2016.012492","article-title":"Survival and toxicity after cisplatin plus etoposide versus carboplatin plus etoposide for extensive-stage small-cell lung cancer in elderly patients.","volume":"12","author":"Hatfield","year":"2016","journal-title":"J Oncol Pract"},{"issue":"11","key":"zoi260929r105","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.annonc.2020.07.011","article-title":"Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up.","volume":"31","author":"Machiels","year":"2020","journal-title":"Ann Oncol"},{"issue":"3","key":"zoi260929r106","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.eururo.2023.04.010","article-title":"European Association of Urology guidelines on testicular cancer: 2023 update.","volume":"84","author":"Patrikidou","year":"2023","journal-title":"Eur Urol"},{"issue":"4","key":"zoi260929r107","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.annonc.2022.01.002","article-title":"Testicular seminoma and non-seminoma: ESMO-EURACAN clinical practice guideline for diagnosis, treatment and follow-up.","volume":"33","author":"Oldenburg","year":"2022","journal-title":"Ann Oncol"},{"issue":"9482","key":"zoi260929r108","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(05)66984-X","article-title":"Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial.","volume":"366","author":"Oliver","year":"2005","journal-title":"Lancet"},{"issue":"4","key":"zoi260929r109","doi-asserted-by":"crossref","first-page":"329","DOI":"10.5306\/wjco.v8.i4.329","article-title":"Platinum-induced neurotoxicity: a review of possible mechanisms.","volume":"8","author":"Kanat","year":"2017","journal-title":"World J Clin Oncol"},{"key":"zoi260929r110","article-title":"Neurotoxicity caused by the treatment with platinum analogues.","volume":"2011","author":"Amptoulach","year":"2011","journal-title":"Chemother Res Pract"},{"key":"zoi260929r18","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. Version 2. National Comprehensive Cancer Network; 2026. Accessed July 3, 2026. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1417"},{"key":"zoi260929r91","unstructured":"PADCEVTM plus Keytruda\u00ae significantly improves survival for patients with muscle-invasive bladder cancer regardless of cisplatin eligibility. Pfizer Inc. December 17, 2025. Accessed February 17, 2026. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/padcevtm-plus-keytrudar-significantly-improves-survival"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2854185\/jimnezlabaig_2026_oi_260929_1788979042.05698.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T15:00:37Z","timestamp":1789657237000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2854185"}},"subtitle":["An Umbrella Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":110,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.34287","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]}}}